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Abstract: The choice of sex in newborns with genital ambiguity is challenging. Information 
concerning the satisfaction of subjects with disorders of sex development from childhood to adulthood 
is required in order to address sex attribution policies. This study focuses on the methods that enable 
clinicians to investigate the alignment of phenotypes with gender identity and quality of life in people 
with disorders of this kind. These methods are presented as tools for studying a cohort of ten subjects 
with 45,X/46,XY mosaicism examined between 1985 and 2014 in the Department of Pediatric 
Endocrinology, Regina Margherita Children’s Hospital, Turin: five children and five young adults, 
four reared as females and six as males. Clinical outcome was assessed by means of a clinical scoring 
system considering height, genital appearance, gonads and pubertal development. The Gender Identity 
Questionnaire for Children and the World Health Organization Quality of Life assessment were 
adopted. The four male children strongly identified with their assigned sex: male attribution was 
satisfactory until pubertal age. In young adults the clinical scores ranged between 55‒65% for both 
genders. In the young male, the reduced sexual activity and the poor body image perception strongly 
affected his quality of life. The clinical scores of the two young female adults (60% for both) were not 
balanced with their quality of life scores (87.5% and 68.75% respectively): individual traits and 
social-familial context should be investigated in order to explain these differences. Clinical and 
psychosocial assessment in people with disorders of sex development is mandatory in order to plan 
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care procedures; a detailed analysis requires adequate tools. Clinical scoring system, Gender Identity 
Questionnaire for Children and World Health Organization Quality of Life assessment can be used to 
investigate the alignment of physical phenotype with gender identity and quality of life. 
Keywords: 45,X/46,XY mosaicism; disorders of sex development; sex attribution; gender identity 
development; quality of life assessment 
Abbreviations: 
DSD = Disorders of Sex Development 
FSH = Follicle Stimulating Hormone 
GIQC = Gender Identity Questionnaire for Children 
hGH = human Growth Hormone 
LH = Luteinizing Hormone 
SHOX = Short Stature Homeobox 
WHOQOL-100 = World Health Organization Quality of Life assessment 
 
1. Introduction 
Disorders of Sex Development (DSD) are congenital conditions defined by atypical 
chromosomal, gonadal or anatomic sex [1]. The estimated incidence of genital ambiguity is 1 in 5000 
to 1 in 4500 births [2,3,4]. The most recent classification is based on chromosomal setting: DSD 
related to sex chromosome abnormalities and DSD related to 46,XY or 46,XX karyotype [5]. 
45,X/46,XY mosaicism, included in sex chromosome abnormalities DSD, have an overall incidence of 
about one in 10.000 [6]. 
45,X/46,XY mosaicism is characterized by heterogeneous clinical presentation [7-10]. Most 
prenatally diagnosed subjects (90‒95%) present normal male phenotype at birth; abnormalities are 
only found in a small percentage (5‒10%) [7,10,11,12]. Data derived from postnatally ascertained 
cases exaggerate the extent of genital and other abnormalities by over representing the phenotypically 
abnormal minority [7]. 
Possible genital presentations are: male or female regular, males with ambiguous features and 
hypovirilization (micropenis, lack of scrotal fusion, incomplete testicular descent, hypospadia) or 
females with ambiguous features and virilization (clitoromegaly, labio-scrotal fusion) [7-10]. Typical 
somatic signs of the Turner syndrome are observed in some cases (palpebral ptosis, epicanthus, 
webbed neck, short stature, shield chest, scoliosis) with possible prenatal and postnatal growth 
retardation [10,13]. Short stature may be the only somatic feature [10,13,14], which is usually related 
to the SHOX (“Short Stature Homeobox”) gene haploinsufficiency in 45,X cell line [15,16]. Some 
development abnormalities can be associated to 45,X/46,XY mosaicism: heart malformations, kidney 
malformations, Meckel diverticulum, bilateral inguinal hernias [7,8]. As regards to gonads, functional 
testes can more often occur and streak or dysgenetic gonads are also possible, even in the presence of 
normal male external genitalia [7]. Gonads can be set at any point of the testicular descent path: streak 
gonads are found most frequently at intra-abdominal level, while regularly developed testes often 
reach inguinal-scrotal level [17]. There is a higher risk of neoplastic transformation in dysgenetic 
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gonads, which is not limited to subjects with abnormal genitalia [7]. The incidence of gonadoblastoma in 
45,X/46,XY individuals is reported to be approximately 15% [11,18]. In rare cases ovary stromal-like 
tissue with scattered primordial follicles has been observed [12]. Müllerian structures are occasionally 
found, resulting from absent or inadequate production of anti-Müllerian hormone by Sertoli cells [12]. 
The treatment of individuals with DSD requires the attention of many professionals. Although the 
medical–surgical treatment is highly important, quality of life also largely depends on the psychosocial 
management [19]. There is little data concerning the clinical course of people with 45,X/46,XY 
mosaicism and, in particular, psychosocial development has not been adequately investigated [20,21]. 
This study focuses on methods that enable clinicians to investigate the alignment of physical 
characteristics, gender identity and quality of life in people with DSD. In particular, the study reports 
the application of these methods to a small cohort of people with 45,X/46,XY. 
2. Materials and Methods 
2.1. Aim 
The aim of the study was to describe the physical phenotypes of a cohort of children and young 
adults with 45,X/46,XY mosaicism, psychosocial features focusing on gender identity in children and 
assessment of quality of life in young adults. A scoring system was proposed in order to make it easier 
to understand the process of gender identification and quality of life in DSD patients with specific 
physical phenotypes.  
2.2. Participants 
We analyzed the personal histories of ten subjects with 45,X/46,XY mosaicism followed up 
between 1985 and 2014 in the Department of Pediatric Endocrinology, Regina Margherita Children’s 
Hospital, Turin: five children and five young adults, four reared as females and six as males. These 
subjects represent the entire consecutive series of patients with 45,X/46,XY mosaicism followed up in 
the hospital in the specific time period.  
Table 1 summarizes clinical presentation, sex of rearing, gonadal features, genitourinary imaging 
and laboratory investigations in the first month of life in the ten subjects with 45,X/46,XY mosaicism. 
Reconstructive and gonadal surgeries are also presented. 
2.3. Measures 
Clinical presentation and history were assessed using specific measures, that are described below. 
For the children, we analyzed gender identification by means of the Gender Identity 
Questionnaire for Children (GICQ), which was filled in by the parents [22]. 
For the young adults we used the World Health Organization Quality of life Assessment 
(WHOQOL-100) [23,24,25] in order to assess their quality of life. 
2.3.1. Clinical presentation at birth and sex of rearing 
Analysis of clinical presentation at birth was based on External Masculinization Score (EMS) [26] 
130 
 
AIMS Genetics  Volume 2, Issue 2, 127-147. 
(Table 2). The scores for each patient are shown in the second column of Table 1. 
When selecting the sex of rearing, genital anatomy, surgical options, need for lifelong hormone 
replacement therapy, potential for fertility were taken into consideration. Genital anatomy was the 
most important aspect on which the decision was based. In the past, the presence of uterus was an 
indication for attributing female sex, while recently parental involvement in the decision has 
progressively grown, since consistent parental support is felt to be critical for the patient for 
assimilating sex assignment. 
2.3.2. Perinatal investigations 
Karyotype 
Due to genital ambiguity at birth, karyotype was carried out on six subjects in order to determine 
the chromosomal sex; it was carried out prenatally for the remaining four by means of amniocentesis 
and was then confirmed at birth. 
Genitourinary imaging 
Genitourinary imaging was obtained by carrying out retrograde genitography and 
abdominopelvic ultrasound, in some cases completed by means of abdomen magnetic resonance. 
Retrograde genitography was performed for the anatomical outlining of the urogenital sinus and for 
localizing the position and entry of the urethra and vagina into the sinus. Abdominopelvic ultrasound 
and abdomen magnetic resonance were used for evaluating internal genitalia. In two subjects, signs of 
genital ambiguity has already been detected with prenatal ultrasound. 
Hormone levels 
The following hormones were investigated using standard methods in the first month of life (from 
10th to 30th day of life): 
 Follicle Stimulating Hormone (FSH); 
 Luteinizing Hormone (LH); 
 Testosterone. 
Comorbidities 
Complete clinical evaluation of each patient, in particular through renal ultrasound and 
echocardiography, was performed at birth in order to detect pathologies of any kind. 
 
131 
 
AIMS Genetics        Volume 2, Issue 2, 127-147. 
Table 1. Early clinical data, sex of rearing and surgical interventions in ten subjects with 45,X/46,XY mosaicism. 
Subject Clinical 
presentation/
Sex of 
rearing 
Reconstructive 
surgery 
(age: years, months) 
Gonadal features Gonadal surgery 
(age: years, 
months) 
Karyotype  Genitourinary imaging Hormone levels 
(10th‒30th day of life)
Comorbidities 
1 EMS 4.5/12 
Female 
Clitoroplasty  
(1, 0/12) 
Vaginoplasty  
(1, 0/12) 
Right gonad:  
streak, 
intra-abdominal 
Left gonad: 
dysgenetic, inguinal
Bilateral 
gonadectomy 
(0, 3/12) 
45,X/46,XY  
prenatal 
(amniocentesis) 
Uterus: present, hypoplastic 
Fallopian tubes: absent  
Urogenital sinus 
FSH 3.6 mU/mL  
LH 2.4 mU/mL  
Testosterone  
0.56 ng/mL  
Horizontal 
nystagmus 
2 EMS 0.5/12
Female 
Vaginoplasty  
(0, 6/12) 
Clitoroplasty  
(0, 6/12–25, 0/12) 
Corrective surgery in 
vaginal introitus 
stenosis (25, 0/12) 
Right gonad: 
streak, 
intra-abdominal 
Left gonad: 
dysgenetic, inguinal
Bilateral 
gonadectomy 
(0, 4/12) 
45,X/46,XY  
postnatal 
Uterus: present, regular structure 
Fallopian tubes: absent 
Urogenital sinus 
FSH 3.5 mU/mL  
LH 2.1 mU/mL  
Testosterone  
0.42 ng/mL 
None 
3 EMS 9.5/12
Female 
Vaginoplasty  
(1, 0/12) 
Clitoroplasty  
(1, 0/12) 
Right gonad: 
streak, inguinal 
Left gonad: 
dysgenetic, 
intrascrotal 
Bilateral 
gonadectomy 
(1, 0/12) 
45,X/46,XY  
prenatal 
(amniocentesis) 
Uterus: present, regular structure  
Fallopian tubes: present on right side 
Female urethra: slightly longer, it 
flows in a small vestibule with a 
vagina of regular morphology 
FSH 3.1 mU/mL  
LH 2.5 mU/mL 
Testosterone  
0.3 ng/mL 
None 
4 EMS 4.5/12
Female 
Vaginoplasty  
(0, 3/12)  
Clitoroplasty  
(0, 3/12) 
Right gonad: 
dysgenetic, inguinal
Left gonad: 
streak, 
intra-abdominal 
Bilateral 
gonadectomy 
(0, 3/12) 
45,X/46,XY  
prenatal 
(amniocentesis) 
Suspected ambiguous genitalia at 
prenatal ultrasound 
Uterus: present, regular structure 
Fallopian tubes: absent 
Vagina with moderate uterine 
impression at cupola level 
Female urethra: straight, veru 
montanum absent, it flows in a large 
vestibule with a vagina of regular 
morphology 
FSH 11.1 mU/mL  
LH 6.14 mU/mL 
Testosterone  
1.12 ng/mL  
None 
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5 EMS 5/12 
Male 
Urethroplasty  
(12, 0/12) 
Testicular prosthesis 
placement  
(18, 10/12) 
Right gonad: streak, 
intra-abdominal 
Left gonad: 
dysgenetic, 
intra-abdominal  
Bilateral 
gonadectomy 
(1, 6/12) 
45,X/46,XYq- 
postnatal 
Uterus: absent 
Fallopian tubes: absent 
Male urethra: hypospadic, veru 
montanum present 
FSH 3.5 mU/mL  
LH 0.7 mU/mL  
Testosterone  
0.8 ng/mL 
None 
6 EMS 6.5/12
Male 
Chordee correction 
(recurvatio corrective 
surgery) (3, 0/12) 
Urethroplasty  
(4, 5/12) 
Right gonad: 
regularly developed, 
intrascrotal 
Left gonad: 
dysgenetic, inguinal
Left gonadectomy
(1, 9/12) 
45,X/46,XY  
postnatal 
Uterus: absent 
Fallopian tubes: absent 
Male urethra: hypospadic, veru 
montanum present 
FSH 5.4 mU/mL 
LH 3.2 mU/mL 
Testosterone  
1.2 ng/mL  
None 
7 EMS 8.5/12
Male 
Chordee correction 
(recurvatio corrective 
surgery) (8, 0/12) 
Urethroplasty  
(8, 0/12) 
Right gonad: 
hypoplastic,  
inguinal  
Left gonad: regularly 
developed, 
intrascrotal 
Right orchidopexy
(6, 0/12) 
45,X/46,XY/4
7,XYY 
postnatal 
Uterus: absent 
Fallopian tubes: absent 
Male urethra: hypospadic 
FSH 4.5 mU/mL 
LH 2.3 mU/mL 
Testosterone  
0.9 ng/mL  
None 
8 EMS 7.5/12
Male 
Chordee correction 
(recurvatio corrective 
surgery) (1, 6/12) 
Urethroplasty (in two 
times)  
(2, 0/12–3, 6/12) 
Right gonad: 
fusiform, inguinal 
Left 
gonad:dysgenetic, 
intra-abdominal 
Right orchidopexy
(0, 3/12) 
Left gonadectomy
(0, 3/12) 
45,X/46,X, 
i(Y)(p11) 
postnatal 
Uterus: absent 
Fallopian tubes: absent 
Male urethra: hypospadic, veru 
montanum present 
FSH 11.2mU/mL 
LH 5.1mU/mL 
Testosterone 1.5ng/mL 
Common 
Atrioventri-
cular 
Chamber 
9 EMS 7.5/12
Male 
Hysterectomy  
(1, 0/12) 
Vaginectomy  
(1, 0/12) 
Urethroplasty (in two 
times)  
(2, 4/12–3, 0/12) 
Right gonad: 
regularly developed, 
inguinal 
Left gonad: streak, 
intra-abdominal 
Right orchidopexy
(0, 4/12) 
Left gonadectomy
(0, 4/12) 
45,X/46,XY  
postnatal 
Suspected ambiguous genitalia at 
prenatal ultrasound 
Uterus: present, regular morphology
Fallopian tubes: present on left side, 
hypoplastic  
Urogenital sinus in which a straight 
urethra flows, veru montanum 
absent 
FSH 1.2 mU/mL  
LH 0.8 mU/mL 
Testosterone  
0.3 ng/mL 
None 
10 EMS 12/12
Male 
None Right gonad: 
regularly developed, 
intrascrotal 
Left gonad: regularly 
developed, 
intrascrotal 
None 45,X/46,XY 
prenatal 
(amniocentesis) 
Uterus: absent 
Fallopian tubes: absent 
Male urethra 
FSH 4.5 mU/mL  
LH 1.4 mU/mL  
Testosterone  
1.3 ng/mL  
None 
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Table 2. External Masculinization Score [26]. 
Feature Score for Yes/No  
or condition 
EMS  
Scrotal fusion 
Micropenis 
Urethral meatus 
- Normal 
- Glandular 
- Penile 
- Perineal 
Right and left gonad (score for each)
- Scrotal 
- Inguinal 
- Abdominal 
- Absent 
3/0 
0/3 
 
3 
2 
1 
0 
 
1.5 
1 
0.5 
0 
2.3.3. Clinical course 
The patients were evaluated and followed up between 1985 and 2014 in the Department of 
Pediatric Endocrinology, Regina Margherita Children’s Hospital, Turin, Italy. The clinical course of 
each subject was monitored with annual outpatient checkups carried out by the pediatric 
endocrinologist as case manager. The clinical history was collected at each checkup, a general physical 
examination was performed and the following parameters were assessed: height, weight, growth rate, 
pubertal development according to Tanner staging [27]. 
In clinical histories, the attitudes and decisions concerning the following issues were analyzed: 
 diagnosis and sex of rearing; 
 reconstructive interventions; 
 cancer risk management and preventive decisions in relation to gonadal function; 
 growth pattern and human growth hormone therapy; 
 pubertal development and sex hormone replacement therapy; 
 gender identity in children and quality of life in young adults. 
At the end of the follow up, in order to evaluate the alignment of phenotypic features to the attributed 
sex, we elaborated a clinical scoring system (rating from 1 = low alignment to 5 = high alignment) relative 
to: height, genital appearance, presence of gonads and pubertal development (Table 3). 
The analysis of clinical histories highlighted a clinical outcome (height reached at the end of the 
follow up, results of reconstructive and gonadal surgeries, pubertal development) which the pediatric 
endocrinologist quantified for each subject by means of the clinical scoring system. The scores are 
shown in Table 4 in the “Total Clinical Scores” column; in the third, fourth, fifth and sixth columns the 
score for each specific feature is reported in brackets. 
In order to evaluate gender identity and quality of life, the children’s parents were given a 
questionnaire on gender identity while the young adults filled in a questionnaire on quality of life.  
At the time of the interview, each subject was informed of the purpose of the study; then the 
patients and the children’s parents released their informed consent. Parental consent was required for 
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those under 14 years of age, for subjects between 14 and 18 years of age the consent of patients and 
their parents was required, while subjects over 18 years of age signed their own informed consent. 
Table 3. Clinical scoring system. 
Feature Score
Height   
< 3rd percentile  
3rd‒10th percentile  
10th‒25th percentile  
25th‒50th percentile  
> 50th percentile 
1 
2 
3 
4 
5 
Male genitals  
hypospadias and recurvatio 
hypospadias and surgically corrected recurvatio  
surgically corrected hypospadias and recurvatio  
surgically corrected hypospadias and no recurvatio  
male normally shaped genitalia 
1 
2 
3 
4 
5 
Female genitals  
clitoral hypertrophy and urogenital sinus 
partial reduction of clitoral hypertrophy and urogenital sinus 
clitoroplasty and vaginoplasty with narrow orifice 
clitoroplasty and vaginoplasty 
female normally shaped genitalia 
1 
2 
3 
4 
5 
Gonads  
bilateral gonadectomy  
unilateral gonadectomy of a streak gonad and contralateral dysgenetic gonad  
bilateral dysgenetic gonads 
unilateral gonadectomy of a streak gonad and contralateral regularly developed gonad  
bilateral regularly developed gonads 
1 
2 
3 
4 
5 
Pubertal development score: according to Tanner staging [27].  
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Table 4. Clinical data at the end of the follow up, clinical scores and GICQ/WHOQOL questionnaires’ results in ten subjects with 45, X/46, XY 
mosaicism. 
Subject Age  
(years, 
month) 
Height 
(clinical 
score) 
Genitalia 
(clinical score) 
Gonads 
(clinical score) 
Pubertal 
development 
(clinical score)
Total 
Clinical 
Score 
Gicq  
score 
Whoqol-100 score Comorbidities 
TOTAL
SCORE
4 FACETS SCORE 
1 33, 0/12 144.1 cm 
<< 3rd 
percentile 
(1) 
Clitoroplasty and 
vaginoplasty 
results  
(4) 
Bilateral gonadectomy 
results 
(1) 
Adult (BV, 
PHV) with 
regular menses
(5) 
11/20 = 
55% 
– – – Recurrent urinary tract 
infections; neurological 
disease (tremors, motor 
incoordination, nystagmus, 
cognitive impairment); 
erythematous desquamative 
chronic dermatitis 
2 31, 0/12 153.5 cm 
3rd–10th 
percentile 
(2) 
Clitoroplasty, 
vaginoplasty and 
corrective surgery 
in vaginal introitus 
stenosis results 
(4) 
Bilateral gonadectomy 
results 
(1) 
Adult (BV, 
PHV) with 
regular menses
(5) 
12/20 = 
60% 
– 87.5% Self-esteem: 87.5% 
Body image: 93.75%
Interpersonal  
relationships: 93.75%
Sexual activity: 
93.75% 
Average: 92.2% 
None 
3 18, 0/12 158.5 cm 
25th 
percentile 
(3) 
Clitoroplasty 
results, presence of 
vaginal introitus 
stenosis 
(3) 
Bilateral gonadectomy 
results 
(1) 
Adult (BV, 
PHV) with 
regular menses
(5) 
12/20 = 
60% 
– 68.75% Self-esteem: 62.5% 
Body image: 56.25%
Interpersonal  
relationships: 68.75%
Sexual activity: 0% 
Average: / 
Overweight 
(BMI: 30 kg/mq), 
autoimmune thyroiditis 
4 1, 0/12 72 cm 
> 50th 
percentile 
(5) 
Clitoroplasty and 
vaginoplasty 
results 
(4) 
Bilateral gonadectomy 
results 
(1) 
Prepubertal 
(–) 
10/15 = 
66.7% 
– – – None 
5 26, 
11/12 
166.2 cm 
> 10th 
percentile 
(3) 
Urethroplasty 
results; intrascrotal 
testicular 
prosthesis 
(4) 
Bilateral gonadectomy 
results 
(1) 
Adult (PHV, 
GV) 
(5) 
13/20 = 
65% 
– – – Slight overweight  
(BMI: 26 kg/mq) 
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6 19, 0/12 152.8 cm 
<< 3rd 
percentile 
(1) 
Chordee correction 
and urethroplasty 
results 
(3) 
Rright gonad: intrascrotal, 
25 mL (periodic monitoring 
with scrotal ultrasound and 
markers assessment: βhCG 
and αFP); 
Left gonad: gonadectomy 
results 
(4) 
Adult (PHV, 
GV) 
(5) 
13/20 = 
65% 
– 43.75% Self-esteem: 81.25%
Body image: 31.25%
Interpersonal  
relationships: 75% 
Sexual activity: 
6.25% 
Average: 48.3% 
Slight overweight  
(BMI: 27.3 kg/mq) 
7 8, 0/12 125.8 cm 
25th–50th 
percentile 
(4) 
Chordee correction 
and urethroplasty 
results 
(3) 
Right gonad: intrascrotal, 1 
mL (periodic monitoring 
with scrotal ultrasound); 
Left gonad: intrascrotal, 2 
mL (periodic monitoring 
with scrotal ultrasound) (5)
Prepubertal 
(–) 
12/15 = 
80% 
4.80/5 
= 96%
– – None 
8 6, 3/12 104.6 cm 
< 3rd 
percentile 
(1) 
Chordee correction 
and urethroplasty 
results 
(3) 
Right gonad: intrascrotal, 
fusiform, 1 mL (periodic 
monitoring with scrotal 
ultrasound); 
Left gonadectomy results 
(2) 
Prepubertal 
(–) 
6/15 = 
40% 
4.90/5 
= 98%
– – Mitral regurgitation of 
moderate degree, 
hemodynamically stable 
(result of intervention to the 
atrioventricular common 
chamber) 
9 5, 2/12 95.5 cm 
< 3rd 
percentile 
(1) 
Vaginectomy and 
urethroplasty 
results 
(3) 
Right gonad: intrascrotal, 2 
mL (periodic monitoring 
with scrotal ultrasound); 
Left gonadectomy results 
(4) 
Prepubertal 
(–) 
8/15 = 
53.3% 
4.80/5 
= 96%
– – None 
10 4, 10/12 110 cm 
50th–75th 
percentile 
(5) 
Normal 
conformed, no 
reconstructive 
surgery (5) 
Intrascrotal, 2 mL (periodic 
monitoring with scrotal 
ultrasound) (5) 
Prepubertal 
(–) 
15/15 = 
100% 
4.36/5 
= 
87.2%
– – None 
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2.4. GIQC—“Gender Identity Questionnaire for Children” 
The 16-item Gender Identity Questionnaire for Children was taken from a study originally carried 
out by P.H. Elizabeth and R. Green in 1984, in order to create a tool that assessed possible problems in 
gender identity development. In 2004 Johnson and colleagues presented the psychometric properties 
of this parent-report instrument after making a few changes. The final 14-item questionnaire has 
excellent psychometric properties, therefore Johnson and colleagues proposed it as a useful and affordable 
screening tool, characterized by quick and easy administration [22]. Each item is rated on a 5-point scale 
for frequency of occurrence, except for 3 items which also have a ‘not applicable’ option; the score 
ranges from 1 (more cross-gendered behavior) to 5 (more same-gendered behavior). A mean GIQC score 
was calculated (gender-referred group mean score: 2.83). 
The Italian version of this questionnaire was developed in the Department of Psychology, at the 
University of Turin using the translation/back-translation method in order to assure equivalence in 
meaning. The pilot study in which the psychometric properties of the tool were explored [28] showed 
that this questionnaire can be used for measuring children’s gender-related behavior in the Italian 
context. The preliminary statistical analysis indicated that excluding two of the items significantly 
increased the reliability of the questionnaire (Cronbach’s Alpha 0.83). The mean score of the 
non-clinical Italian group was 4.31 which was similar to that of the original study carried out by 
Johnson and colleagues in which the control group showed a mean score of 4.20.  
In line with the preliminary results of the pilot study on the Italian version of the GIQC, in our 
data analysis we calculated the score on the 12 items for evaluating our patients. We were able to use 
this tool thanks to the availability and cooperation of the research group from the Department of 
Psychology lead by the scientific coordinator Prof. Piera Brustia. 
2.5. WHOQOL-100—World Health Organization Quality of Life assessment 
The World Health Organization Quality of Life assessment (WHOQOL-100) filled in by the 
young adults was implemented by the World Health Organization in order to develop a quality of life 
assessment that would be applicable cross-culturally [23,24,25]. 
The WHOQOL is divided into six broad domains of quality of life. These are: 
(a) physical domain (the individual’s perception of his/her physical status); 
(b) psychological domain (the individual’s perception of his/her cognitive and affective status); 
(c) level of independence; 
(d) social relationships (the individual's perception of interpersonal relationships and social role); 
(e) environment; and 
(f) spirituality/religion/personal beliefs (the individual's perception of life meaning). 
Within each domain there are several quality of life sub-domains (facets) that summarize the 
particular domain of quality of life. 
This questionnaire provides a percentage global score concerning quality of life (cut off 50%: 
over 50% good quality of life, under 50% poor quality of life), which incorporates 24 specific facets 
belonging to the six domains of Quality of Life [23,24,25].  
In our study, 4 of the 24 facets were assessed due to their important implication in quality of life 
and gender identity:  
1. self-esteem,  
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2. body image,  
3. interpersonal relationships,  
4. sexual activity.  
3. Results 
3.1. Clinical course analysis 
3.1.1. Surgeries and cancer risk management 
The reconstructive and gonadal surgical operations performed on the ten patients and the ages at 
which the operations were carried out are reported in Table 1. 
The four female subjects underwent early feminizing reconstructive surgery. Subject 2 underwent 
corrective surgery in order to repair vaginal introitus stenosis and review clitoroplasty at 25 years of 
age. There is generally need for further intervention of possible vaginal introitus stenosis, subsequent 
to early vaginoplasty in these subjects after pubertal age [1,29,30]. 
The four female subjects underwent early bilateral gonadectomy due to the presence of streak or 
dysgenetic gonads in order to prevent malignancy and psychological problems with the presence of 
testes in subjects reared as females. At histological examination gonadoblastoma was not detected in 
any of the cases. 
In the six male subjects, reconstructive surgery had a greater variability in timing which was often 
performed later in life. Gonadectomy was carried out in the presence of streak or dysgenetic gonads: 
the decision of removing them depended on the absence of hormone production and of 
spermatogenesis process in the presence of significant cancer risk. At histological examination 
gonadoblastoma was not detected in any of the cases.  
Gonadectomy was not performed on subjects with apparently regularly developed testes, because 
of their possible hormone production and consequent spontaneous pubertal development.  
Orchidopexy to the scrotum was performed on cryptorchid subjects.  
3.1.2. Growth and pubertal development: treatment with human Growth Hormone (hGH) and sex 
hormone replacement therapy 
In females, subject 1 received hGH therapy for 7 years (from the age of 9 years and 3 months to 
the age of 16 years and 5 months) and she reached a final height below the 3rd percentile (Figure 1). 
The growth pattern of subject 2 was stable at the 3rd percentile up to 10 years of age, reaching final 
height between the 3rd and 10th percentile following a 6 year course of hGH therapy (from the age of 
10 years and 1 month to the age of 16 years and 3 months) (Figure 1). Subject 3 presented an initially 
normal growth pattern that reached its peak at the 75th percentile at 7 years of age after which there 
was a reduced growth pattern: hGH therapy was carried out from the age of 14 years and 2 months to 
the age of 15 years and 8 months with the achievement of final height at the 25th percentile (Figure 1). 
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The three young adults reared as females underwent sex hormone replacement therapy and 
reached complete adult development (according to Tanner staging) with regular menses (Figure 1). 
Subject 4, a 12-month-old female, has not yet been submitted to any type of therapy. 
In males, particular care was taken when considering hGH therapy due to the possible neoplastic 
risk in their potentially dysgenetic gonads submitted to such a proliferative stimulus. Following early 
bilateral gonadectomy, hGH therapy was administered to subject 5 from the age of 9 years and 8 
months to the age of 15 years and 4 months: he reached final height above the 10th percentile. From the 
age of 12 years and 2 months he was administered testosterone (Figure 2). Therapy with human growth 
hormone was not administered to subject 6 because of noncompliance partially due to his concern 
about the possible neoplastic risk: his final height was below the 3rd percentile. His preserved gonad 
produced testosterone normally and spontaneous pubertal development occurred (Figure 2). The 
growth and gonadal features of the remaining four subjects (7-8-9-10) will be evaluated in the future as 
they were still in childhood at the end of the follow-up. 
3.1.3. Clinical presentation at the end of the follow up 
Table 4 summarizes the clinical presentation of the ten subjects at the end of the follow up in 
relation to the surgical operations and medical therapies carried out. Scores relating to the alignment of 
their phenotypic and functional features to the sex of rearing are presented and converted into 
percentages in order to carry out a more accurate comparison with the results of the questionnaires. 
3.2. Gender identity and quality of life assessment 
Table 4 shows the results of the gender identity questionnaire (GIQC) that was filled in by the 
parents of the four children (subjects 7-8-9-10) reared as males. The scores were high, indicating that 
the children developed and maintained a gender identity commensurate with the assigned sex. 
It was not possible to investigated specific items of gender identity of subject 4 (the only child 
reared as female) since most of gender-related behaviors typically occur from 2‒3 years of age, 
therefore her parents were not requested to fill in the questionnaire. 
The WHOQOL-100 questionnaire was administered to the young adults in order to evaluate 
quality of life and the results are reported in Table 4. 
The WHOQOL-100 questionnaire was not administered to subject 1 (reared as female) due to her 
cognitive impairment and to subject 5 (reared as male) because his family has opposed to prior 
attempts to interview him about his clinical condition. 
3.3. Comparison of clinical scores to gender identity and quality of life scores 
We compared clinical assessment with the results obtained from the questionnaires (GIQC in 
children and WHOQOL-100 in adults) as score percentages.  
3.3.1. Children 
It was not possible to evaluate the female children due to the age of the only child reared as female 
(subject 4). 
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For the male children we compared the clinical scores with the results of the questionnaire on 
gender identity (GIQC) (Table 4). Clinical scores in children included height, genital and gonadal 
features (total score = 15), as it was too early to assess pubertal development.  
The male children developed gender behavior in line with the assigned sex. In subjects 7-8-9 
GICQ score was higher than the clinical score; in subject 10 GICQ score was 87.2%, which was lower 
than the clinical score (100%).  
3.3.2. Adults 
The comparison of the young adults’ clinical scores with the results of WHOQOL-100 
questionnaire is reported in Table 4. The total scores of the 6 areas and of the 24 facets were evaluated. 
Among them, the following facets were subjected to further analysis (4-facets score): 
1. self-esteem,  
2. body image,  
3. interpersonal relationships,  
4. sexual activity. 
For the only two female subjects the comparison between the clinical scores and questionnaire 
results showed that in subject 2 the total quality of life score and the 4-facets score were above 80%, 
thus exceeding the clinical score (60%); in subject 3 the total quality of life score was above 60% and 
similar to the clinical score (60%), while the 4-facets score was incomplete since she declined to 
answer the questions concerning her sexual activity (Table 4). 
For the only young adult male who completed the questionnaire, the total quality of life score and 
the 4-facets score were below 50%, while the clinical score was 60% (Table 4). 
4. Discussion 
Sex of rearing attribution in subjects with disorders of sex development depends on various issues: 
diagnosis, genital anatomy, surgical options, need for lifelong replacement therapy, potential for 
fertility, parental opinion and cultural practices [1,2]. The traditional approach which was mainly 
based on the physician’s perspective and enabled him to attribute female sex on the basis of easier 
surgery [1,31] has progressively been overcome by the growing influence of parental opinion based 
mainly on personal and social experience. Early assignment of sex is necessarily grounded on the 
surrogate will of the parents [32]. Further information regarding the wellbeing of subjects with DSD 
from childhood to adult age is required in order to implement an appropriate strategy for assigning sex. 
There is little or no available data on gender identity in DSD subjects: Meyer-Bahlberg found that, 
in genetic females with congenital adrenal hyperplasia, 5% expressed gender dysphoria, a much higher 
rate than that typically quoted and a few women transitioned from female to male gender [33]; Mazur 
affirmed that gender change from assigned-female to male is nil in complete androgen insensitivity 
syndrome [34]; Cohen-Kettenis and Reiner observed that gender change from female to male occurred 
in approximately 60% of XY DSD individuals who were assigned female as their sex of rearing at birth 
but with normal prenatal testosterone effects [35] and finally it was observed that gender change from 
female to male occasionally occurs in XY DSD individuals with low prenatal testosterone effects almost 
all of whom are assigned female at birth as their sex of rearing [36]. Only few studies regarding gender 
identity and psychosocial development in 45,X/46,XY mosaicism can be found in the literature [20,21]. 
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Considering that active prenatal androgen effects appeared to dramatically increase the likelihood 
of recognition of male sexual identity independent of sex of rearing, we can assume that in our cohort 
there may have been partially deficient prenatal brain androgenisation [37]. 
It is essential to consider that patients with DSD are a heterogeneous group regarding gender 
identity and gender role outcome when planning treatment. In recent years there has been a shift 
toward multidisciplinary evaluation and treatment of DSD with the active involvement of the patient 
and family [38].  
We propose methods for facilitating the association between physical findings and gender 
identification and quality of life in DSD studies. This study reports the use of these methods on a small 
cohort of subjects with 45,X/46,XY mosaicism divided into two age groups: children and young 
adults. 
In children the limitations of our study were incomplete growth and pubertal development. In this 
age group strong identification with the assigned sex was observed, which was even stronger in those 
who had surgically reconstructed genitalia. Previous studies underline that gender identification in 
DSD appears to be less problematic during the early and middle stages of childhood than during 
adolescence and adulthood [39].  
The Gender Identity Questionnaire for Children data show that the four-year-old male child with 
normal genital phenotype (subject 10) had a gender identity score of 87.2%, while the other children 
with genital anomalies had higher identity scores. In our opinion in subject 10, stereotypic male 
behavior, typical of mid childhood, was not so evident considering his age, while in the others, it was 
amplified to confirm the belonging to male gender. Nevertheless it is important to note that during 
childhood the correlation between gender identity and phenotypic appearance can be incomplete. 
Therefore it is essential to follow up the evolution of gender identity in these children especially at 
pubertal age, which is a critical phase for psychosexual development [40]. 
For the young adults quality of life was investigated by means of the WHOQOL questionnaire. 
There is a lack of consensus concerning conceptualization, operational definition and measurement of 
quality of life since it is actually an umbrella term covering various aspects such as functioning, health 
status, perceptions, life conditions, behavior, happiness, lifestyle and symptoms [41]. The WHOQOL 
questionnaire investigates quality of life from a broad perspective including: physical domain, 
psychological domain, level of independence, social relationships, environment and 
spirituality/religion/personal beliefs [23,24,25]. 
In the cases of the two young female adults (subject 2 and 3) the clinical scores were not balanced 
with quality of life scores: in fact they had similar clinical (60% in both) and different quality of life 
scores (87.5 % in subject 2 and 68.75% in subject 3). Additional variables regarding individual traits 
and social-familial context should be investigated in order to explain these differences. These variables 
are neither predictable nor easily editable [42]. Health related quality of life describes a person’s 
satisfaction by integrating current life circumstances as well as the ability to cope and adjust to adversity: 
it is a complex construct that is strongly associated to family life, parents’ responses and well-being, the 
quality of the social environment and other important factors [42]. Quality of life depends on subjective 
appraisal rather than objective measurements [41]. It is preferable to assess overall quality of life rather 
than health-related quality of life and it should be defined and measured in terms of life satisfaction [41]. 
For both sexes it was observed that some specific items reached insufficient scores, especially 
sexual activity and body image for the male (31.25%). This last observation is in line with a previous 
study which found that boys with DSD showed impairment concerning body image: they had a more 
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negative body image of the primary sexual characteristics compared with male controls [43]. It is 
important to remember regarding body image that the male subject had a reduced adult height 
suggesting that the possibility of growth hormone therapy should be carefully considered due to the 
strong effect of being short on body image perception. 
Other studies investigated health-related quality of life in subjects with DSD. Kleinemeier E, 
Jurgensen M, Lux A, et al. observed that the psychological well-being of adolescents with DSD was 
not impaired, but outcomes related to adolescent developmental tasks such as sexual activity showed 
impaired participation and especially girls with DSD reported having fewer sexual activities than 
female controls [43]. For these subjects partnership and sexuality were identified as being difficult 
issues in life [44].  
One of the females from our small cohort did not answer questions related to sexual activity and this 
could be due to difficulty in facing questions regarding sexual matters. Because of the elevated risk of 
sexuality-related problems, adequate and timely counseling regarding sexuality and relationships is of 
great importance: adolescents do not only need medical and sexual education, but they should also have 
the opportunity to discuss their concerns repeatedly with a mental health professional in private [45,46]. 
There is a report in literature claiming that adolescents who needed hormonal treatment to induce 
puberty have impaired well being compared to those who entered puberty spontaneously [43]. It is 
especially important to consider this in subjects reared as male since the risk of neoplastic 
transformation of the gonads should be weighted taking into account the possibility of a spontaneous 
pubertal development in presence of functional testicles.  
5. Conclusion 
Although the proposed scoring system should be tested on a larger control population, the 
comparison of clinical outcome with gender identity and quality of life provided us with important 
information for using a more complete approach for treatment, including psychosocial assessment. 
The results should be carefully interpreted due to the limitations of the study. The findings are not 
easily generalizable since it was an observational study and lacks representativeness of the affected 
population.  
Clinical and psychosocial assessment in people with DSD is mandatory in order to better direct 
care processes and adequate tools are required for a detailed analysis. In this sense the Clinical scoring 
system, the Gender Identity Questionnaire for Children and the World Health Organization Quality of 
Life assessment could prove to be important tools for investigating the alignment of physical 
characteristics and development with gender identity and quality of life. 
Conflict of Interest 
All authors declare no conflicts of interest in this paper. 
References 
1. Lee PA, Houk CP, Ahmed SF, et al. (2006) Consensus statement on management of intersex 
disorders. International Consensus Conference on Intersex. Pediatrics 118: e488-500. 
 
145 
 
AIMS Genetics  Volume 2, Issue 2, 127-147. 
2. Rothkopf AC, John RM (2014) Understanding Disorders of Sexual Development. J Pediatr Nurs 
29: e23-e34 
3. Ahmed SF, Rodie M (2010) Investigation and initial management of ambiguous genitalia. Best 
Pract Res Clin Endocrinol Metab 24: 197-218 
4. Thyen U, Lanz K, Holterhus PM, et al. (2006) Epidemiology and initial management of 
ambiguous genitalia at birth in Germany. Horm Res 66: 195-203 
5. Hughes IA (2008) Disorders of sex development: a new definition and classification. Best Pract 
Res Clin Endocrinol Metab 22: 119-134. 
6. Skakkebaek NE (2003) Testicular dysgenesis syndrome. Horm Res 60: 49. 
7. Chang HJ, Clark RD, Bachman H (1990) The phenotype of 45,X/46,XY mosaicism: an analysis 
of 92 prenatally diagnosed cases. Am J Hum Genet 46: 156-167. 
8. Lindhardt Johansen M, Hagen CP, Rajpert-De Meyts E, et al. (2012) 45,X/46,XY mosaicism: 
phenotypic characteristics, growth, and reproductive function--a retrospective longitudinal study. 
J Clin Endocrinol Metab 97: E1540-1549. 
9. Ocal G, Berberoğlu M, Sıklar Z, et al. (2012) The clinical and genetic heterogeneity of mixed 
gonadal dysgenesis: does ‘disorders of sexual development (DSD)’ classification based on new 
Chicago consensus cover all sex chromosome DSD? Eur J Pediatr 171: 1497-1502. 
10. Telvi L, Lebbar A, Del Pino O, et al. (1999) 45,X/46,XY mosaicism: report of 27 cases. Pediatrics 
104: 304-308. 
11. Cools M, Pleskacova J, Stoop H, et al. (2011) Gonadal pathology and tumor risk in relation to 
clinical characteristics in patients with 45,X/46,XY mosaicism. J Clin Endocrinol Metab 96: 
E1171-1180. 
12. Farrugia MK, Sebire NJ, Achermann JC, et al. (2013) Clinical and gonadal features and early 
surgical management of 45,X/46,XY and 45,X/47,XYY chromosomal mosaicism presenting with 
genital anomalies. J Pediatr Urol 9: 139-144. 
13. Tosson H, Rose SR, Gartner LA (2010) Children with 45,X/46,XY karyotype from birth to adult 
height. Horm Res Paediatr 74: 190-200. 
14. Richter Unruh A, Knauer Fischer S, Kaspers S, et al. (2004) Short stature in children with an 
apparently normal male phenotype can be caused by 45,X/46,XY mosaicism and is susceptible to 
growth hormone treatment. Eur J Ped 163: 251-256. 
15. Rappold GA, Durand C, Decker E, et al. (2012) New roles of SHOX as regulator of target genes. 
Pediatr Endocrinol Rev 9: 733-738. 
16. Rappold GA, Fukami M, Niesler B, et al. (2002) Deletions of the homeobox gene SHOX (short 
stature homeobox) are an important cause of growth failure in children with short stature. J Clin 
Endocrinol Metab 87: 1402-1406. 
17. Vilain E, Sarafoglou K, Yehya N (2009) Disorders of Sex Development. In: Sarafoglou K (ed) 
Pediatric endocrinology and inborn errors of metabolism. New York: McGraw-Hill Medical ; 
London, pp 527-555. 
18. Cools M, Drop SLS, Wolffenbuttel KP, et al. (2006) Germ cell tumors in the intersex gonad: old 
paths, new directions, moving frontiers. Endocr Rev 27: 468-484. 
19. Cohen-Kettenis PT (2009) Psychosocial and psychosexual aspects of disorders of sex 
development. Best Pract Res Clin Endocrinol Metab 24: 325-334.  
20. Szarras-Czapnik M, Lew-Starowicz Z, Zucker KJ (2007) A psychosexual follow-up study of 
patients with mixed or partial gonadal dysgenesis. J Pediatr Adolesc Gynecol 20: 333-338. 
146 
 
AIMS Genetics  Volume 2, Issue 2, 127-147. 
21. Birnbacher R, Marberger M, Weissenbacher G, et al. (1999) Gender identity reversal in an 
adolescent with mixed gonadal dysgenesis. J Pediatr Endocrinol Metab 12: 687-690.  
22. Johnson LL, Bradley SJ, Birkenfeld-Adams AS, et al. (2004) A parent-report gender identity 
questionnaire for children. Arch Sex Behav 33: 105-116. 
23. WHOQOL Group (1998) The World Health Organization Quality of Life Assessment 
(WHOQOL): development and general psychometric properties. Soc Sci Med 46: 1569-1585. 
24. WHOQOL Group (1995) The World Health Organization Quality of Life assessment 
(WHOQOL): position paper from the World Health Organization. Soc Sci Med 41: 1403-1409. 
25. World Health Organization, The World Health Organization Quality of Life (WHOQOL). WHO, 
2013. Available from: http://www.who.int/mental_health/publications/whoqol/en/. 
26. Ahmed SF, Khwaja O, Hughes IA (2000) The role of a clinical score in the assessment of 
ambiguous genitalia. BJU Int 85: 120-124. 
27. Tanner JM, Whitehouse RH (1976) Clinical longitudinal standards for height, weight, height 
velocity, weight velocity, and stages of puberty. Arch Dis Child 51: 170-179. 
28. Caldarera A, Brustia P (2013) Italian version of the GIQC: a preliminary study on the 
psychometric properties. Abstract Book XV Congresso Nazionale della sezione di Psicologia 
clinica e dinamica - AIP, Napoli, Sept. 27-29 (pp.42-43). Napoli: Fridericiana Editrice 
Universitaria. 
29. Alizai NK, Thomas DF, Lilford RJ, et al. (1999) Feminizing genitoplasty for congenital adrenal 
hyperplasia: what happens at puberty? J Urol 161(5): 1588-1591. 
30. Eroğlu E, Tekant G, Gündoğdu G, et al. (2004) Feminizing surgical management of intersex 
patients. Pediatr Surg Int 20: 543-547. 
31. Migeon CJ, Wisniewski AB, Gearhart JP, et al. (2002) Ambiguous genitalia with perineoscrotal 
hypospadias in 46,XY individuals: long-term medical, surgical, and psychosexual outcome. 
Pediatrics 110: e31. 
32. Wiesemann C, Ude-Koeller S, Sinnecker GHG, et al. (2010) Ethical principles and 
recommendations for the medical management of differences of sex development (DSD)/intersex 
in children and adolescents. Eur J Pediatr 169: 671-679. 
33. Meyer-Bahlberg HFL, Gruen RS, New MI, et al. (1996) Gender change from female to male in 
classical conginital adrenal hyperplasia. Horm Behav 30: 319-332. 
34. Mazur T (2005) Gender dysphoria and gender change in androgen insensitivity or micropenis. 
Arch Sex Behav 34: 411-421. 
35. Cohen-Kettenis PT (2005) Gender change in 46,XY persons with 5alphareductase-2 deficiency 
and 17beta-hydroxysteroid dehydrogenase-3 deficiency. Arch Sex Behav 34: 399-410. 
36. Reiner WG, Reiner DT (2012) Thoughts on the Nature of Identity: How Disorders of Sex 
Development Inform Clinical Research about Gender Identity Disorders. J Homosex 59: 434-449. 
37. Reiner WG (2005) Gender Identity and Sex-of-rearing in Children with Disorders of Sexual 
Differentiation. J Pediatr Endocrinol Metab 18: 549-553.  
38. Mattila AK, Fagerholm R, Santtila P, et al. (2012) Gender Identity and Gender Role Orientation in 
Female Assigned Patients with Disorders of Sex Development. J Urol 188: 1930-1934. 
39. Meyer-Bahlburg HFL (1999) Health-related quality of life in intersexuality. Acta Paediatr Suppl 
428: 114-115. 
40. Steensma TD, Kreukels BPC, de Vries ALC, et al. (2013) Gender identity development in 
adolescence. Horm Behav 64: 288-297. 
147 
 
AIMS Genetics  Volume 2, Issue 2, 127-147. 
41. Moons P, Norekval TM (2006) Is sense of coherence a pathway for improving the quality of life of 
patients who grow up with chronic diseases? A hypothesis. Eur J Cardiovasc Nurs 5: 16-20. 
42. Jürgensen M, Lux A, Wien SB, et al. (2014) Health-related quality of life in children with 
disorders of sex development (DSD). Eur J Pediatr 173: 893-903. 
43. Kleinemeier E, Jurgensen M, Lux A, et al. (2010) Psychological Adjustment and Sexual 
Development of Adolescents With Disorders of Sex Development. J Adolesc Health 47: 463-471. 
44. Jürgensen M, Kleinemeier, E, Lux A, et al. (2013) Psychosexual Development in Adolescents and 
Adults with Disorders of Sex Development—Results from the German Clinical Evaluation Study. 
J Sex Med 10: 2703-2714. 
45. Cohen-Kettenis PT (2010) Psychosocial and psychosexual aspects of disorders of sex 
development. Best Pract Res Clin Endocrinol Metab 24: 325-334. 
46. Sandberg DE, Gardner M, Cohen-Kettenis PT (2012) Psychological Aspects of the Treatment of 
Patients with Disorders of Sex Development. Semin Reprod Med 30: 443-452. 
© 2015, Roberta Risso, et al., licensee AIMS Press. This is an open access article distributed 
under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/4.0) 
